Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Corporate Update (January 2011)

29 slides from Auxilium Pharmaceuticals's corporate update, Jan 10, 2011

  1. Slide 1: January 2011

    January 2011 (NASDAQ: AUXL) Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: the pricing, time to market, size of market,

  3. Slide 3: Our Strategy Is to Become a Highly Profitable and Sustainable Biopharmaceutical Company

    Our Strategy Is to Become a Highly Profitable and Sustainable Biopharmaceutical Company Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas

  4. Slide 4: XIAFLEX and Testim Are Global Product Opportunities

    XIAFLEX and Testim Are Global Product Opportunities U.S. Canada EU ROW Open Open Territory XIAFLEX Testim

  5. Slide 5: Auxilium Has a Year Net Revenue CAGR of 40.2%

    Auxilium Has a 6 Year Net Revenue CAGR of 40.2% 4Q10 XIAFLEX Net Revenues $8.4M (including $7.3M in U.S. revenues) 4Q10 Testim Net Revenues $53.4M, 13.3% y/y growth

  6. Slide 6: Slide 6

  7. Slide 7: Dupuytren's Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care

    Dupuytren’s Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care • Excessive collagen in fascia of hand • Nodules or pits are an early, active presentation • Rope-like cords develop in the finger and result in contractures • Quality of life and daily activities affected

  8. Slide 8: We Believe XIAFLEX Is a Paradigm Changing Treatment

    We Believe XIAFLEX Is a Paradigm Changing Treatment • Simple, non-invasive injection of XIAFLEX • Established mechanism of action and selective for specific types of collagen • XIAFLEX’s post-approval profile is consistent with clinical trial experience Pre XIAFLEX injection 30 days following XIAFLE

  9. Slide 9: Strategy for Establishing XIAFLEX as the Standard of Care

    Strategy for Establishing XIAFLEX as the Standard of Care • Disseminate excellent clinical efficacy and safety data • Facilitate peer to peer dialogue • Educate patients on a non-invasive option • Smooth the reimbursement process • Activate a critical mass of experienced prescribers

  10. Slide 10: XIAFLEX Launch Strategy is Tailored to Customer Needs

    XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 6,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini

  11. Slide 11: We Believe the U.S. Dupuytren's Opportunity Is Significant

    We Believe the U.S. Dupuytren’s Opportunity Is Significant 70,000 Surgical 2,3,4 Patients Annually 300,000 Diagnosed Patients Annually 2,3,4 >1 Million Diagnosed Patients 2,4 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data B

  12. Slide 12: Enrollment and Sites that Have Ordered XIAFLEX Are Trending Positively

    Enrollment and Sites that Have Ordered XIAFLEX Are Trending Positively

  13. Slide 13: We Believe that Quarterly XIAFLEX Unit Sales Growth Increased Steadily in 2010

    We Believe that Quarterly XIAFLEX Unit Sales Growth Increased Steadily in 2010 1Q10 2Q10 3Q10 4Q10

  14. Slide 14: Sites Are Increasing XIAFLEX Usage

    Sites Are Increasing XIAFLEX Usage Injections per Site

  15. Slide 15: We Expect the Global Dupuytren's Market to Develop in 2011 and 2012

    We Expect the Global Dupuytren’s Market to Develop in 2011 and 2012 U.S. • XIAFLEX specific J-code J0775 effective Jan. 1 • U.S. CPT code guidance expected for Jan. 2012 • Increasing peer to peer dialogue programs for U.S. physicians • Targeted U.S. patient education campaign planned ROW • Pfizer la

  16. Slide 16: XIAFLEX Revenue Guidance for 2011

    XIAFLEX Revenue Guidance for 2011 U.S. Net Revenues $50 – $60 million Pfizer Royalties & Contract Revenues $5 – $7 million Total Revenues $55 – $67 million

  17. Slide 17: Testim 1% Testosterone Gel

    Testim ® 1% Testosterone Gel • Indicated for testosterone replacement therapy in adult males for hypogonadism • Launched in U.S. in 2003 and EU in 2006 • >7 yrs of use with established safety and efficacy > ~100M daily doses since launch > 16 clinical studies involving approx. 1,800 patients • Appli

  18. Slide 18: Hypogonadism Is an Unmet Need and Under-penetrated Market

    Hypogonadism Is an Unmet Need and Under-penetrated Market • 39% of U.S. males over 45 yrs are hypogonadal > Less than 10% of affected population receives treatment • Increasing physician and patient education and awareness should result in increased treatment Mulligan T. et al. Int J. Clin Pract

  19. Slide 19: Gels Continue to Drive Significant Growth in TRT Marketplace

    Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $198 $281 $334 $371 $439 $545 $685 $892 $1,025 $49 $59 $77 $118 $210 $302 $390 $451 $483 $554 $663 $810 $1,041 1,000 1,200 1,400 Nov Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) Nov 2010 L12M:

  20. Slide 20: Testosterone Replacement Therapy Landscape is Changing

    Testosterone Replacement Therapy Landscape is Changing • New competition in 2011 should help increase overall market – Axiron 2% solution – Fortesta 2% gel – Androgel 1.6% gel seeking approval • Expected further increase in physician and patient education and awareness

  21. Slide 21: Delivering on Current Pipeline

    Delivering on Current Pipeline TESTIM® GEL XIAFLEX® XIAFLEX® XIAFLEX® PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuytren’s contracture Peyronie’s disease Frozen Shoulder Syndrome

  22. Slide 22: Peyronie's disease Is a Devastating Disorder with No Approved Therapies

    Peyronie’s disease Is a Devastating Disorder with No Approved Therapies Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with

  23. Slide 23: We believe Peyronie's Disease Is Under-diagnosed and Under-treated

    We believe Peyronie’s Disease Is Under- diagnosed and Under-treated Bella A. Peyronie’s Disease J Sex Med 2007;4:1527–1538 Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6–23. Mulhall JP, et al. Subjective and objective analysis of the prevalence of Pey

  24. Slide 24: Peyronie's Disease Phase III Development Program

    Peyronie’s Disease Phase III Development Program Study Type ~ # Subjects Sites XIAFLEX: Placebo Duration AUX-CC-803 Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-804 Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-802 Open Label 12 US 6 NZ 18 EU N/A 36 Wks AUX-CC-

  25. Slide 25: We Believe Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III

    We Believe Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III • 4 cycles of therapy in the phase III trial • All patients receive modeling in the phase III trial • All patients must have greater than 12 months of disease since diagnosis to enter the phase III tr

  26. Slide 26: Business Development Efforts Focused on Building Out Pipeline

    Business Development Efforts Focused on Building Out Pipeline • Leverage current infrastructure of Testim and XIAFLEX field forces with marketed products • Seeking Phase II and later assets in Urology, Endocrinology, Rheumatology, and Orthopedics • Niche products with specialty physician call points

  27. Slide 27: 2010 Preliminary Net Revenue

    Testim U.S. $52.1 23.3% $190.0 25.0% Testim Ex U.S. & Contract $1.3 (73.7%) $3.0 (64.2%) Testim Total $53.4 13.3% $193.0 20.3% 2010 Preliminary Net Revenue Q4 ’10 Growth Growth ($ Millions) vs. 2009 Full Year vs. 2009 XIAFLEX U.S. $7.3 - $14.1 - XIAFLEX Contract $1.1 22.1% $4.3 22.1% XIAFLEX Total $

  28. Slide 28: Strategic Priorities in 2011

    Strategic Priorities in 2011 • Maximize XIAFLEX net revenues for Dupuytren’s contracture in the U.S. • Support Pfizer in the launch of Dupuytren’s contracture in the EU • Enroll Peyronie’s disease phase III clinical program • Projected double-blind study enrollment to be completed in 1Q11 • Phase II

  29. Slide 29: Our Strategy Is to Become a Highly Profitable and Sustainable Biopharmaceutical Company

    Our Strategy Is to Become a Highly Profitable and Sustainable Biopharmaceutical Company Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas

Auxilium Pharmaceuticals — Corporate Update (January 2011) on 6ix